Lactose India Shareholders Approve Vitanosh Merger

Lactose India shareholders have overwhelmingly backed the proposed merger with Vitanosh Ingredients at an Extra Ordinary General Meeting (EOGM) held on March 28, 2026. The decision, called by the National Company Law Tribunal (NCLT), clears a significant hurdle for the consolidation.

While the deal aims to boost Lactose India's manufacturing capacity and product range, potential integration challenges and Vitanosh's recent net loss are points for investors to monitor.

Vote Details

The shareholder support was substantial. Out of 541,433 shares voted, an overwhelming 541,418 were in favour, with only 15 against. This strong endorsement signals confidence in the merger's strategic direction.

Strategic Goals and Backstory

The merger is designed to enhance Lactose India's operational capabilities and market presence. By combining forces, the company expects to unlock economies of scale, streamline operations, and potentially introduce higher-margin lactose products like Inhalation Grade and Spray Dried Lactose. This move is supported by prior approvals, including the NCLT Ahmedabad Bench's first motion clearance in February 2026 and a no-objection letter from the BSE in August 2025.

The consolidation will also shift Lactose India's ownership structure. Promoter and Promoter Group shareholding is expected to rise to 58.84% from the current 53.65%, consolidating control.

Key Impacts of the Merger

Following the merger, Lactose India's manufacturing capacity is set to expand by 50%, increasing from 10,000 MT to 15,000 MT per annum. This expansion, along with a broadened product portfolio, is anticipated to drive future revenue growth. On the financial front, Lactose India will assume Vitanosh Ingredients' net loss of ₹1.96 crore from FY2025, a factor that may affect short-term profitability. Public shareholders' stake will adjust to 41.16%.

Potential Risks

Despite the strong shareholder vote, several risks remain. The merger is still contingent on obtaining all necessary statutory and regulatory clearances, which could cause delays. Managing the integration of Vitanosh's operations and its FY2025 net loss of ₹1.96 crore will require careful financial oversight to mitigate any adverse short-term impact on earnings. Successfully realizing the anticipated synergies and avoiding operational disruptions is critical.

Looking Ahead

Investors will be watching for the finalization of regulatory approvals and the timeline for their completion. Key focus areas will also include management's strategy for integrating Vitanosh's operations and finances, and the combined entity's performance as it absorbs the new losses and leverages its expanded capacity and product range.